Latest Conference

At Digestive Disease Week, Paul Feuerstadt MD, FACG, AGAF and fellow investigators explore the potential impact of non-antibiotic medications on gut health and their association with recurrent CDI.

A comparative study presented MAD-ID, The Antimicrobial Stewardship Meeting examining the effectiveness of ceftaroline and vancomycin in addressing this challenge.

A study presented at The Annual Conference on Vaccinology Research (ACVR) offers insights into the efficacy of seasonal influenza vaccines.

This study, presented at MAD-ID, The Antimicrobial Stewardship Meeting, evaluates patients with mild COVID-19 symptoms compared to those with severe cases.

Trial analyses presented at MAD-ID, The Antimicrobial Stewardship Meeting, highlight the battle against recurrent health care-associated infections (HAI).

The PERSEUS study aimed to assess the effectiveness and safety of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin presented at the 34th ESCMID Global conference.

Insights from the Annual Conference on Vaccinology Research (ACVR) in mitigating severe outcomes in older adults and individuals with underlying medical conditions.

Insights from the Annual Conference on Vaccinology Research (ACVR) on vaccine registries and assessing the safety of maternal and fetal health.

A study presented at ESCMID examines the efficacy and safety of the vaccine in older populations.

A study presented at ESCMID aims to understand ribotype 955 as a new challenge in C difficile management.

C-SMART trial results presented at ESCMID show a reduction of COVID-19 incidence in cancer patients.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

A novel approach using this emerging technology looks to interfere with antibiotic resistance expression and reduce this global health issue.

Insights into host-directed therapies (HDT) for tuberculosis (TB) gaining traction among experts aiming to combat the disease's various forms, including drug-resistant strains.

Monika Pogorzelska-Maziarz, epidemiologist, health services researcher, and associate professor at Thomas Jefferson University, shares insights on COVID-19's influence in acute care hospitals at this year’s Society for Healthcare Epidemiology of America (SHEA) conference.

The streptococcal pneumoniae urine antigen (SPUA) test was studied over the course of a year to determine if it provided any benefits in terms of diagnostic capability or aided in reducing empirical antibiotic use.

The results were presented at the Society for Healthcare Epidemiology of America (SHEA) conference, highlighting this first documented case of C auris moving from an adult to a pediatric unit within the state.

A study, presented at the Society for Healthcare Epidemiology of America (SHEA) conference, assesses laxative administration before CDI testing in Veteran Affairs (VA) hospitals and explores the demographic and contextual factors with non-adherence to guidelines.

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Study proves the role of harnessing CrAgSQ for management over the infection.

The impact of remdesivir across age groups.

Customizing treatment strategies for enhanced outcomes and longevity.

Defense against omicron in HIV-positive patients post-COVID.

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Insights from CROI on the HepB-CpG vaccine trial.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

Unraveling monocyte activation and the implications for cardiovascular risk

A reduced risk of individual symptoms associated with the condition was reported when patients were administered the therapy within 2 days of admittance.

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.